Aggregate value of common shares reserved for future issuance.

No definition available.

Name:	nxtc_CommonStockCapitalSharesValueReservedForFutureIssuance
Namespace Prefix:	nxtc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	nxtc_LicenseAgreementLineItems
Namespace Prefix:	nxtc_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount payable upon qualifying event under the licensing agreement.

+ References

No definition available.

+ Details

Name:	nxtc_LicensingAgreementAmountPayable
Namespace Prefix:	nxtc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of consideration for acquiring rights under the licensing agreements.

+ References

No definition available.

+ Details

Name:	nxtc_LicensingAgreementConsiderationToAcquireRights
Namespace Prefix:	nxtc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of expense pertaining to rights under the licensing agreements.

+ References

No definition available.

+ Details

Name:	nxtc_LicensingAgreementExpense
Namespace Prefix:	nxtc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of milestone payments to be made upon achievement of events.

+ References

No definition available.

+ Details

Name:	nxtc_LicensingAgreementMilestonePayments
Namespace Prefix:	nxtc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of cash outflow pertaining to upfront payment under the licensing agreements.

+ References

No definition available.

+ Details

Name:	nxtc_LicensingAgreementUpfrontCashPayment
Namespace Prefix:	nxtc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	srt_StatementScenarioAxis=nxtc_UponInitiationOfFirstPhase1ClinicalTrialForSim0505Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=nxtc_UponInitiationOfFirstPhase2ClinicalTrialForSim0505Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=nxtc_UponAchievingDevelopmentAndRegulatoryMilestoneOfZaimingProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=nxtc_UponAchievingDevelopmentAndRegulatoryMilestoneOfNextcureProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=nxtc_UponAchievingCommercialSalesBasedMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License Agreement (Details) - USD ($) $ in Millions	Jun. 13, 2025	Oct. 31, 2025
License Agreement
Consideration agreed	$ 17.0
Upfront cash payment	12.0
Consideration payable	5.0
License agreement expense	18.5
Upon initiation of the first Phase 1 clinical trial for SIM0505
License Agreement
Consideration agreed	1.5
Upon initiation of the first Phase 2 clinical trial for SIM0505
License Agreement
Value of stock agreed to be issued	1.0
Upon achieving development and regulatory milestone of Zaiming Product
License Agreement
Consideration payable		$ 1.5
Upon achieving development and regulatory milestone of Zaiming Product \| Maximum
License Agreement
Milestone payments	166.5
Upon achieving development and regulatory milestone of NextCure Product \| Maximum
License Agreement
Milestone payments	25.5
Upon achieving commercial sales-based milestone \| Maximum
License Agreement
Milestone payments	$ 535.0